Literature DB >> 12680824

Is clinical growth index a reliable predictor of tumour growth in vestibular schwannomas?

A Mohyuddin1, E A Vokurka, D G R Evans, R T Ramsden, A Jackson.   

Abstract

We have assessed the clinical growth index as an indicator of tumour growth rate in 50 patients with a vestibular schwannoma. Clinical growth index was calculated by measuring the length of history and dividing it by the maximum tumour diameter. Total tumour volumes were also measured from all MRI examinations and an effective tumour volume doubling time was calculated. Radiological growth measurements demonstrated involution in 10/50 patients. The median volume doubling time was 1.65 years (range 20.9-46.3 months, skewness 1.72 years). The median clinical growth index was 0.030 cm per month (range 0-0.270 cm per month, skewness 2.398). There was no significant correlation between volume doubling time and clinical growth index. Identification of rapidly growing tumours with clinical growth index >0.025 cm/month had a positive predictive value of 61%, negative predictive value of 48%, false-positive rate of 30% and false-negative rate of 52%. In conclusion, we have shown that the growth rate of vestibular schwannoma is not related to the clinical growth index and we recommend that this measure should be abandoned in the clinical management of patients where conservative management regimes are being considered.

Entities:  

Mesh:

Year:  2003        PMID: 12680824     DOI: 10.1046/j.1365-2273.2003.00670.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  9 in total

1.  Pretreatment ADC Values Predict Response to Radiosurgery in Vestibular Schwannomas.

Authors:  A Camargo; T Schneider; L Liu; J Pakpoor; L Kleinberg; D M Yousem
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-13       Impact factor: 3.825

2.  Determination of the clinical growth index in unilateral vestibular schwannoma.

Authors:  Marc Diensthuber; Thomas Lenarz; Timo Stöver
Journal:  Skull Base       Date:  2006-02

3.  Long-term outcomes of vestibular schwannomas treated with fractionated stereotactic radiotherapy: an institutional experience.

Authors:  Sumit Kapoor; Sachin Batra; Kathryn Carson; John Shuck; Siddharth Kharkar; Rahul Gandhi; Juan Jackson; Jan Wemmer; Stephanie Terezakis; Ori Shokek; Lawrence Kleinberg; Daniele Rigamonti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-09-29       Impact factor: 7.038

4.  Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation.

Authors:  C Warren; L A James; R T Ramsden; A Wallace; M E Baser; J M Varley; D G Evans
Journal:  J Med Genet       Date:  2003-11       Impact factor: 6.318

5.  Genetic and epigenetic alterations of the NF2 gene in sporadic vestibular schwannomas.

Authors:  Jong Dae Lee; Tae Jun Kwon; Un-Kyung Kim; Won-Sang Lee
Journal:  PLoS One       Date:  2012-01-25       Impact factor: 3.240

6.  Multiple retroperitoneal schwannomas mimicking adrenal tumors.

Authors:  Koichi Oishi; Toshiyuki Itamoto; Sho Okimoto; Takashi Nishisaka
Journal:  Case Rep Oncol       Date:  2012-05-08

7.  Identifying predictors of early growth response and adverse radiation effects of vestibular schwannomas to radiosurgery.

Authors:  Soroush Larjani; Eric Monsalves; Houman Pebdani; Boris Krischek; Fred Gentili; Michael Cusimano; Normand Laperriere; Caroline Hayhurst; Gelareh Zadeh
Journal:  PLoS One       Date:  2014-10-22       Impact factor: 3.240

Review 8.  The controversy about a possible relationship between mobile phone use and cancer.

Authors:  Michael Kundi
Journal:  Environ Health Perspect       Date:  2008-09-26       Impact factor: 9.031

9.  Spontaneous shrinkage of vestibular schwannoma.

Authors:  Rossana Romani; Jonathan Pollock
Journal:  Surg Neurol Int       Date:  2016-05-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.